As of 2025-09-13, the EV/EBITDA ratio of Cytokinetics Inc (CYTK) is -8.74. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CYTK's latest enterprise value is 4,963.19 mil USD. CYTK's TTM EBITDA according to its financial statements is -568.10 mil USD. Dividing these 2 quantities gives us the above CYTK EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.1x - 17.4x | 15.7x |
| Forward P/E multiples | 22.6x - 32.7x | 27.8x |
| Fair Price | (160.30) - (124.85) | (154.30) |
| Upside | -413.5% - -344.2% | -401.8% |
| Date | EV/EBITDA |
| 2025-09-11 | -9.06 |
| 2025-09-10 | -8.87 |
| 2025-09-09 | -8.79 |
| 2025-09-08 | -8.88 |
| 2025-09-05 | -9.02 |
| 2025-09-04 | -8.53 |
| 2025-09-03 | -8.57 |
| 2025-09-02 | -8.51 |
| 2025-08-29 | -6.39 |
| 2025-08-28 | -6.69 |
| 2025-08-27 | -6.76 |
| 2025-08-26 | -6.82 |
| 2025-08-25 | -6.64 |
| 2025-08-22 | -6.84 |
| 2025-08-21 | -6.80 |
| 2025-08-20 | -6.69 |
| 2025-08-19 | -6.76 |
| 2025-08-18 | -6.93 |
| 2025-08-15 | -6.89 |
| 2025-08-14 | -6.89 |
| 2025-08-13 | -6.62 |
| 2025-08-12 | -6.24 |
| 2025-08-11 | -6.08 |
| 2025-08-08 | -6.21 |
| 2025-08-07 | -6.38 |
| 2025-08-06 | -6.36 |
| 2025-08-05 | -6.51 |
| 2025-08-04 | -6.58 |
| 2025-08-01 | -6.59 |
| 2025-07-31 | -6.73 |
| 2025-07-30 | -6.52 |
| 2025-07-29 | -6.48 |
| 2025-07-28 | -6.58 |
| 2025-07-25 | -6.67 |
| 2025-07-24 | -6.69 |
| 2025-07-23 | -6.78 |
| 2025-07-22 | -6.74 |
| 2025-07-21 | -6.63 |
| 2025-07-18 | -6.67 |
| 2025-07-17 | -6.92 |
| 2025-07-16 | -6.89 |
| 2025-07-15 | -6.79 |
| 2025-07-14 | -6.87 |
| 2025-07-11 | -6.64 |
| 2025-07-10 | -6.58 |
| 2025-07-09 | -6.58 |
| 2025-07-08 | -6.23 |
| 2025-07-07 | -6.10 |
| 2025-07-03 | -6.29 |
| 2025-07-02 | -6.25 |